0001209191-19-050455.txt : 20190923
0001209191-19-050455.hdr.sgml : 20190923
20190923161922
ACCESSION NUMBER: 0001209191-19-050455
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190920
FILED AS OF DATE: 20190923
DATE AS OF CHANGE: 20190923
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MERRIWEATHER ALFRED G
CENTRAL INDEX KEY: 0001211839
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36399
FILM NUMBER: 191108235
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001328143
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 421560076
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1900 POWELL ST., SUITE 1000
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 510-450-3554
MAIL ADDRESS:
STREET 1: 1900 POWELL ST., SUITE 1000
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050524
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-20
0
0001328143
Adamas Pharmaceuticals Inc
ADMS
0001211839
MERRIWEATHER ALFRED G
C/O ADAMAS PHARMACEUTICALS, INC.
1900 POWELL ST., SUITE 1000
EMERYVILLE
CA
94608
0
1
0
0
Chief Financial Officer
Common Stock
2019-09-20
4
S
0
1584
6.91
D
48019
D
Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
The shares were sold at prices ranging from $6.89 to $6.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Jennifer Rhodes, Attorney-in-fact
2019-09-23